News Section

  ARMGO Pharma Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for ARM210/S48168 for the Treatment of Duchenne Muscular Dystrophy
Link to Press Release

  ARMGO Pharma and Servier Announce Advancement of Rycal ARM210/S48168 into Clinical Stage Program Targeting Duchenne Muscular Dystrophy
Link to Press Release

  ARMGO Pharma Receives Research Grant Award from Kennedy's Disease Association to Support Advancement of Rycal Compounds
Link to Press Release

  ARMGO Pharma Receives $1 Million Award from MDA to Support Advancement of Rycal Compound ARM210 as a Novel Treatment for Duchenne Muscular Dystrophy
Link to Press Release

  ARMGO Pharma Announces Data Which Supports its Rycal Program as a Novel Approach for the Treatment of Stress-induced Cognitive Disorders
Link to Press Release

  Researchers Identify Potential Treatment for Cognitive Effects of Stress-Related Disorders, including PTSD
Link to Press Release

  Study Explains Why Muscles Weaken with Age and Points to Possible Therapy
Link to Press Release

  ARMGO Pharma, Inc. announces the appointment of Dr. Sapan Shah as CEO
Link to Announcement


Selected Publications

  Fauconnier et al., Ryanodine receptor leak mediated by caspase-8 activation leads to left ventricular injury after myocardial ischemia-reperfusion.   Link to Article
  Andersson, Daniel C, et al. Ryanodine Receptor Oxidation Causes Intracellular Calcium Leak and Muscle Weakness in Aging Cell Metab. 2011 Aug 3;14(2):196-207.
  Meli AC, Refaat MM, Dura M, et al. A Novel Ryanodine Receptor Mutation Linked to Sudden Death Increases Sensitivity to Cytosolic Calcium.Circ Res.2011   Link to Article
  Prof. Andrew Marks presentation on, "Mechanism-Based Therapies for Heart Failure and Cardiac Arrhythmias" from the Henry Stewart Talks, Series, "Calcium Signalling: Regulation, Mechanisms, Effectors, Role in Disease and Recent Advances".   Link to Article
  Bellinger AM, Reiken S, Carlson C, et al. Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nature Medicine 2009;15:325-330.   Link to Article
  Bellinger AM, Reiken S, Dura M, et al. Remodeling of ryanodine receptor complex causes “leaky” channel: a molecular mechanism for decreased exercise capacity. Proc Natl Acad Sci U S A. 2008;105:2198-2202.   Link to Article
  Lehnart SE, Mongillo M, Lindegger N, et al. Leaky Ca2+ release channel/ryandodine receptor 2 causes seizures and sudden cardiac death in mice.. J.Clin.Invest. 2008;118(6):2230-45. Link to Article
  Wehrens X, Lehnart SE, Reiken S, et al. Ryanodine receptor/calcium release channel PKA phosphorylation: a critical mediator of heart failure progression. Proc Natl Acad Sci U S A. 2006;103:511-8.   Link to Article
  Huang F, Shan j, Reiken S, et al. Analysis of calstabin2(FKBP12.6)-ryanodine receptor interactions: rescue of heartfailure by calstabin2 in mice. Proc Natl Acad Sci U S A. 2006;103:3456-61.   Link to Article
  Lehnart SE, Terrenoire C, Reiken S, et al. Stabilization of cardiac ryanodine receptor prevents intracellular calcium leak and arrhythmias. Proc Natl Acad Sci U S A. 2006;103(20):7906-10.   Link to Article
  Lehnart SE, Wehrens XH, Marks AR. Ryanodine receptors as drug targets for heart failure and cardiac arrhythmias. Drug Discoveries Today. 2005;2:259-269.   
  Lehnart S, Wehrens X, Reiken S, et al. Phosphodiesterase 4D deficiency in the ryanodine receptor complex promotes heart failure and arrhythmias. Cell. 2005;123:25-35.    Link to Article
  Wehrens XH, Lehnart SE, Reiken SR, et al. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science. 2004;304:292-296.
  Wehrens XH, Marks AR. Novel therapeutic approaches for heart failure by normalizing calcium cycling. Nature Reviews 2004;3:1-9.   
  Wehrens XH, Lehnart SE, Huang F, et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death.Cell. 2003;113:829-840.    Link to Article
  Marx SO, Reiken S , Hisamatsu y, et al. PKA Phosphorylation Dissociates FKBP12.6 from the Calcium Release Channel(Ryanodine Receptor):Defective Regulation in failing hearts.Cell. 2000;101:365-376.    Link to Article

For Information:


Contact ARMGO® at:

ARMGO Pharma, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591
Phone: 914-425-0000
Fax: 914-425-0032